iPS cell

iPS cell. An induced pluripotent stem cell is a type of pluripotent stem cell that can be generated directly from a somatic cell through the introduction of specific genes. This revolutionary technology, which bypasses the need for embryos, has transformed the fields of regenerative medicine and developmental biology. The discovery earned Shinya Yamanaka the Nobel Prize in Physiology or Medicine in 2012, shared with John Gurdon.

History and discovery

The conceptual foundation was laid by earlier work on nuclear transfer and cloning, notably the creation of Dolly the sheep by researchers at the Roslin Institute. The direct breakthrough came in 2006 when Shinya Yamanaka and his team at Kyoto University successfully reprogrammed mouse fibroblasts. They identified a core set of transcription factors, later known as the Yamanaka factors, sufficient to induce pluripotency. This seminal work was published in the journal Cell. Subsequent research, including pivotal contributions from James Thomson at the University of Wisconsin–Madison, rapidly confirmed the technique with human cells.

Generation and reprogramming

The standard method involves introducing defined factors into somatic cells, typically using retrovirus or lentivirus vectors. The original combination, the Yamanaka factors, includes OCT4, SOX2, KLF4, and MYC. Alternative cocktails and methods have since been developed, such as the use of episomal vectors, Sendai virus, or small molecule compounds to improve safety and efficiency. The reprogramming process resets the epigenetic landscape of the cell, erasing DNA methylation patterns and modifying histone marks to establish a pluripotent state akin to that of an embryonic stem cell.

Characteristics and properties

These cells exhibit the two defining hallmarks of pluripotency: the ability to self-renew indefinitely in culture and the potential to differentiate into derivatives of all three germ layers—ectoderm, endoderm, and mesoderm. They express key pluripotency markers like NANOG and SSEA-4. Functionally, they can form teratomas when injected into immunodeficient mice and contribute to chimeric embryos. Their gene expression profile and DNA methylation status are extensively compared to embryonic stem cell lines in databases like the Human Pluripotent Stem Cell Registry.

Applications and research

A primary application is in disease modeling, where cells from patients with conditions like Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis are reprogrammed to create in vitro models for study. They are crucial for drug discovery and toxicity testing, exemplified by projects like the StemBANCC consortium. In regenerative medicine, clinical trials are underway for conditions including age-related macular degeneration and spinal cord injury. Pioneering work at institutions like the RIKEN Center for Developmental Biology has advanced their use in cell therapy.

Ethical considerations

The technology alleviates major ethical controversies associated with the destruction of human embryos required for embryonic stem cell research, a debate highlighted during the George W. Bush administration. However, new ethical discussions concern the potential for creating human gametes or human-animal chimeras, as explored in research at the Salk Institute. Issues of informed consent for cell donors and patent disputes, such as those involving the Wisconsin Alumni Research Foundation, also present ongoing challenges.

Challenges and limitations

Significant hurdles remain, including the risk of tumorigenesis due to the integration of oncogenes like MYC or incomplete reprogramming. There is also variability in the differentiation potential and epigenetic memory between different cell lines. Large-scale production for therapies faces obstacles in achieving Good Manufacturing Practice standards and controlling costs. Furthermore, ensuring functional integration and avoiding immune rejection in transplant recipients, despite the autologous nature of the cells, are active areas of investigation at centers like the Harvard Stem Cell Institute.